Please assess the completion status of the following clinical trial:

Trial Title: Ethiopia Antimalarial in Vivo Efficacy Study 2012

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Slide-confirmed infection with P. vivax~* Age \> 1 year~* Lives within 20 km of the enrolling health facility~* Weight ≥ 5.0 kg~* Axillary temperature ≥ 37.5º C or history of fever during the previous 48 hours~* Patient or caregiver agrees to all finger pricks and return visits.~Exclusion Criteria:~* General danger signs or symptoms of severe malaria (see Annex II)~* Signs or symptoms of severe malnutrition, defined as weight-for-age ≤ 3 standard deviations below the mean (NCHS/WHO normalized reference values)~* Slide confirmed infection with any other Plasmodium species. besides P. vivax mono-infection~* Acute anemia, defined as Hg \< 8 g/dl~* Known hypersensitivity to any of the drugs being evaluated~* Presence of febrile conditions caused by diseases other than malaria~* Serious or chronic medical condition by history (cardiac, renal, hepatic diseases, sickle cell disease, HIV/AIDS)~* Pregnant or breastfeeding women.~* History or hemolysis or severe anemia~* Regular medication, which may interfere with antimalarial pharmacokinetics

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Artemether-lumefantrine (Type: ACTIVE_COMPARATOR): Weight-based dose to be administered as fixed-dose combination twice daily for three days.
- Artemether-lumefantrine and primaquine (Type: EXPERIMENTAL): Artemether-lumefantrine will be given in a weight-based dose to be administered as fixed-dose combination twice daily for three days.~Primaquine will be given beginning on day 2 of artemether-lumefantrine to patients with a normal G6PD test; dose is weight-based to be administered once daily for 14 days.
- Chloroquine (Type: ACTIVE_COMPARATOR): Chloroquine will be given in a weight-based dose to be administered once daily for three days.
- Chloroquine and primaquine (Type: EXPERIMENTAL): Chloroquine will be given in a weight-based dose to be administered once daily for three days.~Primaquine will be given beginning on day 2 of chloroquine to patients with a normal G6PD test; dose is weight-based to be administered once daily for 14 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).